What Cipher Pharmaceuticals does

Cipher Pharmaceuticals is a publicly traded specialty pharmaceutical company headquartered in Mississauga, Ontario, that acquires and commercializes differentiated prescription products in dermatology and anti-parasitic therapeutics. Its commercial portfolio is anchored by Natroba (spinosad), an FDA-approved topical treatment for head lice and scabies acquired from ParaPRO in July 2024 for US$89.5M, and Epuris, the leading isotretinoin product for severe acne with 45% Canadian market share. The company sells Natroba in the US through a 50-person specialty field sales force targeting dermatologists, family practitioners, infectious disease specialists, and pediatricians, and markets Epuris in Canada through its domestic sales infrastructure.

Cipher generates revenue through direct product sales (Natroba in the US, Epuris in Canada), licensing royalties (Absorica portfolio licensed to Sun Pharmaceuticals in the US, Epuris in Mexico via Galephar/Italmex), and out-licensed products such as Lipofen. The April 2026 launch of a CaryHealth-powered direct-to-patient platform extends Natroba's access model through telehealth consultations and same-day pharmacy delivery. Out-licensed products and pipeline assets (MOB-015 for nail fungus, CF-101 for psoriasis, DTR-001 for tattoo removal) round out the franchise.

The company operates with high gross margins (Natroba at 83%, blended Q4 2025 at 81%), $5M of outstanding debt against $6.4M of cash and an $85M available credit facility as of March 2026, and a market capitalization of approximately C$425.48M. Cipher's strategy centers on a buy-and-commercialize model supplemented by US platform expansion out of Carmel, Indiana, with active business development for additional acquisitions and licensing deals.

Name

Cipher Pharmaceuticals

Legal name

Cipher Pharmaceuticals Inc.

Website

https://cipherpharma.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Cipher Pharmaceuticals is a TSX-listed specialty pharmaceutical company that acquires and commercializes differentiated dermatology and anti-parasitic prescription products, anchored by Natroba (head lice/scabies) in the US and Epuris (isotretinoin) in Canada.

Ownership category

akta.pro rank

Product category

Specialty Dermatology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Dermatology & Topical Skin Treatments (HLAIADAE)

Keywords

• Specialty pharmaceuticals
• Dermatology treatments
• Prescription therapeutics
• Anti-parasitic medications
• Isotretinoin products

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Technology or R&D, Operations

Revenue model

1. Product Revenue: Direct product sales primarily in Canada (Epuris and other dermatology products) and US (Natroba through acquired commercial operations). Revenue from Canadian portfolio was $4.5M in Q1 2026 and Natroba contributed $6.9M in Q1 2026.
2. Licensing Revenue: Royalties and licensing fees from partnered products including Absorica portfolio in US (Sun Pharmaceuticals), Epuris in Mexico (Galephar/Italmex), and net sales royalties. Licensing revenue was $1.1M in Q1 2026, up 52% year-over-year.
3. Natroba US Operations: Acquired US-based commercial operations including direct sales of Natroba and authorized generic Spinosad through 50-person sales force. Generated $30M in product revenue in 2025 with 83% gross margin.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels3 records

Core offering

Cipher Pharmaceuticals is a specialty pharmaceutical company that develops, acquires, and commercializes differentiated prescription products primarily in dermatology and anti-parasitic treatments. Its portfolio includes Natroba (spinosad) for head lice and scabies, Epuris (isotretinoin) for severe acne, out-licensed products such as the Absorica portfolio and Lipofen, and a late-stage pipeline including MOB-015 for onychomycosis, CF-101 for psoriasis, and DTR-001 for tattoo removal. The company markets products through a US field sales force, Canadian sales infrastructure, and international licensing partners.

Product overview

Cipher Pharmaceuticals is a specialty pharmaceutical company with a diversified portfolio of commercial and pipeline products, primarily focused on dermatology. The core commercial products include Natroba (spinosad), an FDA-approved prescription treatment for head lice and scabies acquired from ParaPRO in July 2024, and Epuris, the leading isotretinoin acne treatment in Canada. The company also has out-licensed products including the Absorica isotretinoin portfolio and Lipofen. The pipeline includes MOB-015 for nail fungus (Canadian rights held), CF-101 for psoriasis, and DTR-001 for tattoo removal. Cipher markets products directly in Canada and the U.S., and through partners in South America.

Differentiator

Problem solved

Functional benefit

Brands

• Natroba: Topical prescription treatment for head lice and scabies; acquired from ParaPRO in July 2024
• Epuris
• Absorica
• Lipofen

Products and services

• Natroba (Spinosad) A topical prescription treatment for head lice and scabies. It is the only FDA-approved prescription head lice treatment with a 'Complete Cure' designation and demonstrated clinical superiority to Nix in phase III trials. The scabies indication carries FDA exclusivity and patent protection until 2033. Acquired from ParaPRO in July 2024.
• Epuris An isotretinoin product for the treatment of severe acne. It is the #1 prescribed isotretinoin product by dermatologists in Canada with 45% market share. Launched in Mexico in May 2023 through partnerships with Italmex and Galephar.
• Absorica Portfolio
• Lipofen

Quantifiable outcome

• Natroba achieved $30M revenue with 83% gross margin in 2025 (first partial year post-acquisition)
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• CaryHealthcoreStrategic or Co-development Partner · 7 April 2026Partnership to launch direct-to-patient platform for Natroba, integrating telehealth consultations, same-day pharmacy delivery, and prescription tracking. Platform replaces fragmented virtual-care workflows with unified digital-first access model.
• ParaPRO LLCcoreStrategic or Co-development Partner · 29 July 2024Cipher acquired global product rights for Natroba (Spinosad) and ParaPRO's US commercial sales team of 50 employees for $89.5 million ($80M cash + $9.5M in Cipher shares). ParaPRO founder continues involvement and became Cipher's second largest shareholder. Cipher gained US headquarters in Carmel, Indiana and platform for future dermatology product launches.
• Moberg Pharma ABcoreStrategic or Co-development PartnerCipher holds exclusive Canadian rights to MOB-015 (nail fungus treatment). Moberg obtained EU approval for MOB-015 across 13 countries and completed Phase 3 enrollment in North America with topline results expected January 2025. Cipher preparing Health Canada regulatory submission.
• Galephar Pharmaceutical ResearchminorChannel Partner/ Reseller/ DistributorPartnership for commercial manufacturing and distribution of Epuris in Mexico. Galephar's partner Italmex Pharma handles commercial launch, with Epuris officially launched in Mexico in May 2023.
• Italmex Pharma S.A.minorChannel Partner/ Reseller/ DistributorCommercial partner for Epuris launch in Mexico through partnership with Galephar. Generated $0.1M royalty revenue in Q2 2023 from initial sales.
• Sun PharmaceuticalscoreChannel Partner/ Reseller/ DistributorExtended distribution and supply agreement for Absorica portfolio in US through December 2026 (Absorica, Absorica AG) and December 2024 (Absorica LD). Cipher receives licensing revenue from product shipments and royalties.
• Sun Pharmaceuticals (Arbitration)minorOthersCipher received favorable arbitration award against Sun Pharmaceuticals regarding dispute over clinical data and contractual obligations. Arbitrator declared Cipher owner of data and awarded damages and future royalties. Sun filed petition seeking to vacate parts of award.
• Canfite BiopharmaminorStrategic or Co-development PartnerCipher holds exclusive Canadian rights to CF-101 (Piclidenoson) for treatment of moderate to severe psoriasis. Partner received positive FDA feedback on registration plan for pivotal Phase III trial and Phase III COMFORT study met primary endpoint of superiority.

Scale indicators14 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Padagis: Specialty pharma focused on dermatology, pain, and women's health, with branded and complex generic products. Comparable specialty pharma peer with similar product acquisition strategy and North American commercial footprint.
• ParaPRO LLC: Former owner of Natroba (Spinosad), whose commercial team and global product rights Cipher acquired in July 2024 for $89.5M. Direct historical peer in the lice/scabies prescription market and continuing partner relationship.
• Mayne Pharma Group: Australian specialty pharma with dermatology and women's health franchises, including branded and generic dermatology products. Comparable small-cap specialty pharma with similar mix of in-licensed and acquired dermatology assets serving physicians.
• Galderma: Pure-play global dermatology company with leading prescription and aesthetic product portfolios across acne, rosacea, and skin conditions. Highly comparable to Cipher as a focused dermatology specialty pharma serving physicians and consumers worldwide.
• Leo Pharma: Privately-held specialty dermatology company with a portfolio spanning psoriasis, atopic dermatitis, and skin infections. Direct peer in dermatology specialty pharma with comparable physician-targeted commercial models and Nordic HQ similar to Cipher's small-cap scale.
• Moberg Pharma AB: Swedish specialty pharma developing MOB-015 (nail fungus) — Cipher's exclusive Canadian licensing partner. Directly comparable as a small dermatology-focused pharma with a single-asset commercialization model in the same nail fungus category.

Emerging players

• Arcutis Biotherapeutics: US-listed late-stage dermatology company focused on immuno-dermatology (psoriasis, atopic dermatitis, seborrheic dermatitis). Comparable small-cap dermatology specialty peer with similar commercial-stage strategy and physician sales force build-out.
• Dermavant Sciences: Emerging dermatology company developing topical therapies for inflammatory skin conditions. Comparable emerging peer in dermatology specialty pharma with pipeline-stage assets targeting similar physician specialties.

Broad incumbents

• Bausch Health Companies: Large diversified specialty pharma with a major dermatology franchise (Ortho Dermatologics) covering acne, psoriasis, and actinic keratosis. While much broader than Cipher, it competes in the same dermatology prescription channels and physician relationships.
• Taro Pharmaceutical Industries: Generic-focused specialty pharma with a dermatology generics portfolio serving US and Canadian markets. Comparable as a dermatology-focused pharma operating in both the US and Canada, though at a much larger scale and with a generics rather than branded focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cipher Pharmaceuticals